echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Inject innovation power into a healthy China

    Inject innovation power into a healthy China

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The epidemic is devastating human health, but it also makes innovation a daily routine.


    The epidemic is devastating human health, but it also makes innovation a daily routine.


    "We are soberly aware that the cycle of new infectious diseases facing mankind has a significantly shortened trend, and the'ultimate weapon' to overcome the epidemic is science and technology, especially drug research and development including vaccines.


    The new crown pneumonia epidemic is like a surprise inspection of the public health undertakings of various countries.


    Innovative drugs bring the gospel Innovative drugs bring the gospel Innovative drugs bring the gospel

    Just after the Lunar New Year in 2021, Xu Jianmin, director of the Colorectal Cancer Center of Zhongshan Hospital, Fudan University, returned to the hospital early for rounds.


    Just after the Lunar New Year in 2021, Xu Jianmin, director of the Colorectal Cancer Center of Zhongshan Hospital, Fudan University, returned to the hospital early for rounds.


    The colorectal surgery where Xu Jianmin works mainly treats patients with colorectal cancer.


    Cancer is the second leading cause of death in the world, and the incidence of colorectal cancer has risen to the third place in China's cancer spectrum.


    The latest report of "Jointly Innovative Medicine Industry, Helping the Construction of a "Healthy China"" issued by the Pharmaceutical Research and Development Industry Committee of the China Association of Foreign Investment Enterprises (RDPAC) also shows that the research and development and popularization of breakthrough innovative drugs have effectively improved the middle and advanced stages of cancer.


    These five years are not only a simple addition to the life span of patients, but also mean that patients can have a longer time to wait for new drugs to be launched.


    The improvement of the conditions of cancer patients is only one aspect of the innovative medicine industry's contribution to the construction of a healthy China.


    In addition, these innovations in the medical field are not only a blessing to patients, but also have multiple values ​​to the health system and broader society.


    In short, with the rapid development of domestic medical level and pharmaceutical research and development, the health level of residents has been significantly improved.


    "The achievements in the fields of public health, medical care, medical insurance, and pharmaceuticals, which together constitute the strategic framework of Healthy China, have also provided support for the rapid prevention and control of the epidemic and the phased victory of the overall war.


    Accelerated entry of new overseas drugs, accelerated entry of new overseas drugs, accelerated entry of new overseas drugs

    Wang Hao (pseudonym) has inherited many advantages of his mother, but also inherited a problem that causes "foot pain" from time to time.


    Wang Hao (pseudonym) has inherited many advantages of his mother, but also inherited a problem that causes "foot pain" from time to time.


    For a patient with a rare disease, Wang Hao is lucky.
    For a patient with a rare disease, Wang Hao is lucky.

    Because, on June 6, 2020, only one year after his diagnosis, China's first drug "Fabuzan" approved for patients diagnosed with Fabry disease was launched in China, and it was already in the country in May of that year.
    More than ten cities started supplying medicine.
    Among these cities where medicine is supplied, Shanghai where Wang Hao lives is included.

    Because, on June 6, 2020, only one year after his diagnosis, China's first drug "Fabuzan" approved for patients diagnosed with Fabry disease was launched in China, and it was already in the country in May of that year.
    More than ten cities started supplying medicine.
    Among these medicine-supply cities is Shanghai where Wang Hao lives.
    Because, on June 6, 2020, only one year after his diagnosis, China's first drug "Fabuzan" approved for patients diagnosed with Fabry disease was launched in China, and it was already in the country in May of that year.
    More than ten cities started supplying medicine.
    Among these cities where medicine is supplied, Shanghai where Wang Hao lives is included.

    In recent years, the country has successively introduced a series of favorable policies concerning rare disease treatment drugs, which has given many rare disease patients like Wang Hao a "new life" in the "new drugs".
    In March 2019, the National Medical Products Administration proposed to establish a special review mechanism for overseas new drugs that are urgently needed clinically.
    The approval time for rare disease treatment drugs is within 3 months.
    This is one of the main reasons why drugs for the treatment of rare diseases such as "Fabuzin" can successfully pass the review and be launched quickly.

    In recent years, the country has successively introduced a series of favorable policies concerning rare disease treatment drugs, which has given many rare disease patients like Wang Hao a "new life" in the "new drugs".
    In March 2019, the National Medical Products Administration proposed to establish a special review mechanism for overseas new drugs that are urgently needed clinically.
    The approval time for rare disease treatment drugs is within 3 months.
    This is one of the main reasons why drugs for the treatment of rare diseases such as "Fabuzin" can successfully pass the review and be launched quickly.
    In recent years, the country has successively introduced a series of favorable policies concerning rare disease treatment drugs, which has given many rare disease patients like Wang Hao a "new life" in the "new drugs".
    In March 2019, the National Medical Products Administration proposed to establish a special review mechanism for overseas new drugs that are urgently needed clinically.
    The approval time for rare disease treatment drugs is within 3 months.
    This is one of the main reasons why rare disease treatment drugs like "Fabuzin" can successfully pass the review and be quickly launched.

    Not only rare diseases, according to RDPAC statistics, in the past five years, a total of 200 new drugs have been listed in China, focusing on the three major areas of tumor, cardiovascular system and digestion/metabolism.
    Among them, multinational pharmaceutical companies contributed 156 innovative products, accounting for up to 80%.

    Not only rare diseases, according to RDPAC statistics, in the past five years, a total of 200 new drugs have been listed in China, focusing on the three major areas of tumor, cardiovascular system and digestion/metabolism.
    Among them, multinational pharmaceutical companies contributed 156 innovative products, accounting for up to 80%.
    Not only rare diseases, according to RDPAC statistics, in the past five years, China has launched a total of 200 new drugs, focusing on the three major areas of cancer, cardiovascular system and digestion/metabolism.
    Among them, multinational pharmaceutical companies contributed 156 innovative products, accounting for up to 80%.

    More and more innovative drugs have entered the country, which has greatly changed the survival status of domestic patients.
    Some once incurable diseases have turned into chronic diseases, and even have the possibility of curing.
    For some diseases that are still difficult to be completely cured, new technologies can also extend the survival time of patients and improve the quality of life.

    More and more innovative drugs have entered the country, which has greatly changed the survival status of domestic patients.
    Some once incurable diseases have turned into chronic diseases, and even have the possibility of curing.
    For some diseases that are still difficult to be completely cured, new technologies can also extend the survival time of patients and improve the quality of life.
    More and more innovative drugs have entered the country, which has greatly changed the survival status of domestic patients.
    Some once incurable diseases have turned into chronic diseases, and even have the possibility of curing.
    For some diseases that are still difficult to be completely cured, new technologies can also extend the survival time of patients and improve the quality of life.

    It is worth noting that, "Although the domestic review and approval of overseas new drugs that are urgently needed for clinical purposes has been accelerating, some overseas pharmaceutical companies are still worried about entering the Chinese market.
    " Wang Yiou, founder of the Pain Challenge Foundation, explained to a reporter from "Global" magazine "The first is the lack of market momentum.
    Although some overseas new drugs have entered the Chinese market, due to high prices, domestic patients have limited ability to pay, and it is difficult for companies to judge the return on research and development; the second is that they have concerns about domestic intellectual property protection, such as in The protection of the development of indications after the expiration of the patent, or the protection of the registration data of biological drugs, etc.
    "

    It is worth noting that, "Although the domestic review and approval of overseas new drugs that are urgently needed for clinical purposes has been accelerating, some overseas pharmaceutical companies are still worried about entering the Chinese market.
    " Wang Yiou, founder of the Pain Challenge Foundation, explained to a reporter from "Global" magazine "The first is the lack of market momentum.
    Although some overseas new drugs have entered the Chinese market, due to high prices, domestic patients have limited ability to pay, and it is difficult for companies to judge the return on R&D; the second is that there are concerns about domestic intellectual property protection, such as in After the expiration of the patent, the protection of the development of indications, or the protection of the registration data of biological drugs, etc.
    ” It is worth noting that “Although the domestic review and approval of foreign new drugs that are urgently needed for clinical purposes has been speeding up, some overseas pharmaceutical companies are not The Chinese market is still very worried.
    ” Wang Yiou, founder of the Pain Challenge Foundation, explained to a reporter from Global magazine, “First, market momentum is insufficient.
    Although some overseas new drugs have entered the Chinese market, the price of domestic patients is too high, and the ability of domestic patients to pay is limited.
    It is difficult for companies to judge the return on research and development; second, they have concerns about domestic intellectual property protection, such as the protection of indication development after patent expiration, or the protection of registration data of biological drugs.
    "

    Wang Yiou said that the above problems are more prominent in the field of rare diseases.
    Because the target drug population is small, clinical trials are difficult to carry out, and profits cannot be guaranteed.
    Moreover, many companies that develop orphan drugs for rare diseases are small and medium-sized enterprises and do not have the ability to enter overseas markets.
    ability.
    Therefore, among the 121 rare diseases included in the "First Batch of Rare Disease Catalogue", there are still nearly 20 rare diseases that have medicines abroad and no medicines in China.
    Patients lack the opportunity to take medicine, and even patients with rare diseases have to obtain corresponding medicines through "overseas purchasing agents".

    Wang Yiou said that the above problems are more prominent in the field of rare diseases.
    Because the target drug population is small, clinical trials are difficult to carry out, and profits cannot be guaranteed.
    Moreover, many companies that develop orphan drugs for rare diseases are small and medium-sized enterprises and do not have the ability to enter overseas markets.
    ability.
    Therefore, among the 121 rare diseases included in the "First Batch of Rare Disease Catalogue", there are still nearly 20 rare diseases that have medicines abroad and no medicines in China.
    Patients lack the opportunity to take medicine, and even patients with rare diseases have to obtain corresponding medicines through "overseas purchasing agents".
    Wang Yiou said that the above problems are more prominent in the field of rare diseases.
    Because the target drug population is small, clinical trials are difficult to carry out, and profits cannot be guaranteed.
    Moreover, many companies that develop orphan drugs for rare diseases are small and medium-sized enterprises and do not have the ability to enter overseas markets.
    ability.
    Therefore, among the 121 rare diseases included in the "First Batch of Rare Disease Catalogue", there are still nearly 20 rare diseases that have medicines abroad and no medicines in China.
    Patients lack the opportunity to take medicine, and even patients with rare diseases have to obtain corresponding medicines through "overseas purchasing agents".

    Don't let new drugs out of reach

    Don't make new medicines out of reach Don't make new medicines out of reach Don't make new medicines out of reach

    Xu Jianmin said that the most painful thing for him was the many patients who came to Zhongshan Hospital from other places for medical treatment.
    After returning to the local chemotherapy, some targeted drugs are difficult to buy due to different medical insurance policies in different regions, or because the burden is too heavy, or the treatment by local doctors.
    The concept is different, thus giving up targeted therapy.

    Xu Jianmin said that the most painful thing for him was the many patients who came to Zhongshan Hospital from other places for medical treatment.
    After returning to the local chemotherapy, some targeted drugs are difficult to buy due to different medical insurance policies in different regions, or because the burden is too heavy, or the treatment by local doctors.
    The concept is different, thus giving up targeted therapy.
    Xu Jianmin said that the most painful thing for him was the many patients who came to Zhongshan Hospital from other places for medical treatment.
    After returning to the local chemotherapy, some targeted drugs are difficult to buy due to different medical insurance policies in different regions, or because the burden is too heavy, or the treatment by local doctors.
    The concept is different, thus giving up targeted therapy.

    The clinical and social value of innovative drugs is very clear on a global scale, but compared with Western countries, the availability and usage of innovative drugs are still relatively low in China.

    The clinical and social value of innovative drugs is very clear on a global scale, but compared with Western countries, the availability and usage of innovative drugs are still relatively low in China.
    The clinical and social value of innovative drugs is very clear on a global scale, but compared with Western countries, the availability and usage of innovative drugs are still relatively low in China.

    "The approval of the marketing of an innovative drug does not mean that patients can benefit immediately.
    The biggest gatekeeper in China is medical insurance.
    At present, the medical insurance department has great influence.
    It determines whether to enter the medical insurance catalog and determine the reimbursement after entering.
    The ratio affects the availability and affordability of innovative drugs for patients.
    ” Liu Yuanli said.

    "The approval of the marketing of an innovative drug does not mean that patients can benefit immediately.
    The biggest gatekeeper in China is medical insurance.
    At present, the medical insurance department has great influence.
    It determines whether to enter the medical insurance catalog and determine the reimbursement after entering.
    The ratio affects the availability and affordability of innovative drugs for patients.
    ” Liu Yuanli said.
    "The approval of the marketing of an innovative drug does not mean that patients can benefit immediately.
    The biggest gatekeeper in China is medical insurance.
    At present, the medical insurance department has great influence.
    It determines whether to enter the medical insurance catalog and determine the reimbursement after entering.
    The ratio affects the availability and affordability of innovative drugs for patients.
    ” Liu Yuanli said.

    In the past few years, phased achievements have been made in the negotiation and implementation of the National Medical Insurance Catalogue.
    In 2017, 36 drugs were included in the National Medical Insurance List through negotiations, and drug prices fell by an average of 44%, which greatly reduced the medical burden of patients.
    In 2019, the National Medical Insurance Bureau negotiated 97 clinically necessary and effective drugs into the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drug catalogs.
    After entering, the average price of drugs dropped by 60.
    7%.
    In the process of the implementation of the policy, due to the differences in reimbursement policies and fund operations in various regions, the proportion of patients who receive negotiated drug treatments is still relatively high.

    In the past few years, phased achievements have been made in the negotiation and implementation of the National Medical Insurance Catalogue.
    In 2017, 36 drugs were included in the National Medical Insurance List through negotiations, and drug prices fell by an average of 44%, which greatly reduced the medical burden of patients.
    In 2019, the National Medical Insurance Bureau negotiated 97 clinically necessary and effective drugs into the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drug catalogs.
    After entering, the average price of drugs dropped by 60.
    7%.
    In the process of the implementation of the policy, due to the differences in reimbursement policies and fund operations in various regions, the proportion of patients who receive negotiated drug treatments is still relatively high.
    In the past few years, phased achievements have been made in the negotiation and implementation of the National Medical Insurance Catalogue.
    In 2017, 36 drugs were included in the National Medical Insurance List through negotiations, and drug prices fell by an average of 44%, which greatly reduced the medical burden of patients.
    In 2019, the National Medical Insurance Bureau negotiated 97 clinically necessary and effective drugs into the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drug catalogs.
    After entering, the average price of drugs dropped by 60.
    7%.
    In the process of the implementation of the policy, due to the differences in reimbursement policies and fund operations in various regions, the proportion of patients who receive negotiated drug treatments is still relatively high.

    For example, in the field of rare diseases, Wang Yiou introduced that although the Basic Medical Insurance Drug List has included 55 rare disease treatment drugs for 24 rare diseases in the First Batch of Rare Disease List, there are still some rare disease drugs that have not yet entered the national medical insurance.
    , The scope of protection is still limited.
    Moreover, there are currently no national-level policies that provide for the protection of drugs for rare diseases.
    Therefore, in the case of an effective treatment plan, whether patients with rare diseases can obtain treatment and medicines is still greatly dependent on the local policies of the government where the household registration is located.
    In the absence of the corresponding reimbursement medical system guarantee, some families of rare disease patients cannot afford to pay for the treatment at their own expense, and have to give up treatment or return to poverty due to illness or cause poverty due to illness.

    For example, in the field of rare diseases, Wang Yiou introduced that although the Basic Medical Insurance Drug List has included 55 rare disease treatment drugs for 24 rare diseases in the First Batch of Rare Disease List, there are still some rare disease drugs that have not yet entered the national medical insurance.
    , The scope of protection is still limited.
    Moreover, there are currently no national-level policies that provide for the protection of drugs for rare diseases.
    Therefore, in the case of an effective treatment plan, whether patients with rare diseases can obtain treatment and medicines is still greatly dependent on the local policies of the government where the household registration is located.
    In the absence of the corresponding reimbursement medical system guarantee, some families of rare disease patients cannot afford to pay for the treatment at their own expense, and have to give up treatment or return to poverty due to illness or cause poverty due to illness.
    For example, in the field of rare diseases, Wang Yiou introduced that although the Basic Medical Insurance Drug List has included 55 rare disease treatment drugs for 24 rare diseases in the First Batch of Rare Disease List, there are still some rare disease drugs that have not yet entered the national medical insurance.
    , The scope of protection is still limited.
    Moreover, there are currently no national-level policies that provide for the protection of drugs for rare diseases.
    Therefore, in the case of an effective treatment plan, whether patients with rare diseases can obtain treatment and medicines is still greatly dependent on the local policies of the government where the household registration is located.
    In the absence of the corresponding reimbursement medical system guarantee, some families of rare disease patients cannot afford to pay for the treatment at their own expense, and have to give up treatment or return to poverty due to illness or cause poverty due to illness.

    In 2020, RDPAC conducted a survey on the drug protection situation of patients with national negotiated drugs.
    The results showed that among the 1502 interviewees who used the national drug, 60.
    5% of the respondents said that the inclusion of drugs in medical insurance has a significant effect on reducing the burden of costs.
    32.
    0% indicated that the self-financed rate of annual treatment costs had been reduced by 10% to 50%, and 28.
    6% indicated that it had been reduced by more than 50%.
    However, it is worth noting that there are still 23.
    2% of patients who said that they did not actually benefit from national negotiations, and 3.
    3% of patients even said that the proportion of personal burden has increased.

    In 2020, RDPAC conducted a survey on the drug protection situation of patients with national negotiation drugs.
    The results showed that among 1502 interviewees who used national negotiation drugs, 60.
    5% of the respondents indicated that the inclusion of drugs in medical insurance has a significant effect on reducing the cost burden.
    32.
    0% indicated that the self-financed rate of annual treatment costs had been reduced by 10% to 50%, and 28.
    6% indicated that it had been reduced by more than 50%.
    However, it is worth noting that there are still 23.
    2% of patients who said that they did not actually benefit from national negotiations, and 3.
    3% of patients even said that the proportion of personal burden has increased.
    In 2020, RDPAC conducted a survey on the drug protection situation of patients with national negotiation drugs.
    The results showed that among 1502 interviewees who used national negotiation drugs, 60.
    5% of the respondents indicated that the inclusion of drugs in medical insurance has a significant effect on reducing the cost burden.
    32.
    0% indicated that the self-financed rate of annual treatment costs had been reduced by 10% to 50%, and 28.
    6% indicated that it had been reduced by more than 50%.
    However, it is worth noting that there are still 23.
    2% of patients who said that they did not actually benefit from national negotiations, and 3.
    3% of patients even said that the proportion of personal burden has increased.

    Liu Yuanli analyzed that the largest user of innovative drugs in China is public hospitals, and public hospitals are not only affected by the "zero markup" policy (hospitals have no incentive to use innovative drugs), but are also restricted by collective bidding and procurement policies (public hospitals can These policies limit the hospital’s impulse to "prescribe large prescriptions", which controls the unnecessary burden of patients and social security to a certain extent, but at the same time it also affects drugs.
    The accessibility of drugs, in particular, limits the timely use and development of innovative drugs.

    Liu Yuanli analyzed that the largest user of innovative drugs in China is public hospitals, and public hospitals are not only affected by the "zero markup" policy (hospitals have no incentive to use innovative drugs), but are also restricted by collective bidding and procurement policies (public hospitals can These policies limit the hospital’s impulse to "prescribe large prescriptions", which controls the unnecessary burden of patients and social security to a certain extent, but at the same time it also affects drugs.
    The accessibility of drugs, in particular, limits the timely use and development of innovative drugs.
    Liu Yuanli analyzed that the largest user of innovative drugs in China is public hospitals, and public hospitals are not only affected by the "zero markup" policy (hospitals have no incentive to use innovative drugs), but are also restricted by collective bidding and procurement policies (public hospitals can These policies limit the hospital’s impulse to "prescribe large prescriptions", which controls the unnecessary burden of patients and social security to a certain extent, but at the same time it also affects drugs.
    The accessibility of drugs, in particular, limits the timely use and development of innovative drugs.

    Xu Jianmin also said that clinicians are often "stretched" in the application of innovative drugs.
    At present, items related to diagnosis and treatment expenses such as "proportion of drugs" and "average cost" occupy an important position in the performance evaluation of hospitals and clinicians.
    Compared with clinical examination and traditional chemotherapy drugs, the cost of targeted therapy drugs is an order of magnitude higher, significantly increasing the "drug share" and "average cost".
    "Every year at the end of the year, the oncology departments of each hospital are the key targets of criticism.
    Therefore, sometimes clinicians have to reduce the use of such drugs.
    " Xu Jianmin was rather helpless when it came to these.

    Xu Jianmin also said that clinicians are often "stretched" in the application of innovative drugs.
    At present, items related to diagnosis and treatment expenses such as "proportion of drugs" and "average cost" occupy an important position in the performance evaluation of hospitals and clinicians.
    Compared with clinical examination and traditional chemotherapy drugs, the cost of targeted therapy drugs is an order of magnitude higher, significantly increasing the "drug share" and "average cost".
    "Every year at the end of the year, the oncology departments of each hospital are the key targets of criticism.
    Therefore, sometimes clinicians have to reduce the use of such drugs.
    " Xu Jianmin was rather helpless when it came to these.
    Xu Jianmin also said that clinicians are often "stretched" in the application of innovative drugs.
    At present, items related to diagnosis and treatment expenses such as "proportion of drugs" and "average cost" occupy an important position in the performance evaluation of hospitals and clinicians.
    Compared with clinical examination and traditional chemotherapy drugs, the cost of targeted therapy drugs is an order of magnitude higher, significantly increasing the "drug share" and "average cost".
    "Every year at the end of the year, the oncology departments of each hospital are the key targets of criticism.
    Therefore, sometimes clinicians have to reduce the use of such drugs.
    " Xu Jianmin was rather helpless when it came to these.

    Getting through the new drug can reach the "last mile"

    Getting through the new drug can reach the "last mile" Getting through the new drug can get to the "last mile" Getting through the new drug can get to the "last mile"

    The interviewed experts unanimously stated that to ensure that innovative drugs can truly enter the hospital and benefit patients, a multi-faceted security system needs to be established.

    The interviewed experts unanimously stated that to ensure that innovative drugs can truly enter the hospital and benefit patients, a multi-faceted security system needs to be established.
    The interviewed experts unanimously stated that to ensure that innovative drugs can truly enter the hospital and benefit patients, a multi-faceted security system needs to be established.

    First of all, we must do a good job in hospitals, improve doctors' awareness of innovative drugs, and increase the clinical use rate of innovative drugs.
    At the same time, continue to deepen the reform of the medical and health system.
    In 2019, the General Office of the State Council issued the Opinions on Strengthening the Performance Appraisal of Tertiary Public Hospitals, proposing the use of relevant indicators of rational drug use instead of the proportion of single drugs used for assessment, and the rationality of each prescription of medical staff and the patient's drug use.
    Quality and safety are placed in a more prominent position, and relevant indicators are assessed.

    First of all, we must do a good job in hospitals, improve doctors' awareness of innovative drugs, and increase the clinical use rate of innovative drugs.
    At the same time, continue to deepen the reform of the medical and health system.
    In 2019, the General Office of the State Council issued the Opinions on Strengthening the Performance Appraisal of Tertiary Public Hospitals, proposing the use of relevant indicators of rational drug use instead of the proportion of single drugs used for assessment, and the rationality of each prescription of medical staff and the patient's drug use.
    Quality and safety are placed in a more prominent position, and relevant indicators are assessed.
    First of all, we must do a good job in hospitals, improve doctors' awareness of innovative drugs, and increase the clinical use rate of innovative drugs.
    At the same time, continue to deepen the reform of the medical and health system.
    In 2019, the General Office of the State Council issued the Opinions on Strengthening the Performance Appraisal of Tertiary Public Hospitals, proposing the use of relevant indicators of rational drug use instead of the proportion of single drugs used for assessment, and the rationality of each prescription of medical staff and the patient's drug use.
    Quality and safety are placed in a more prominent position, and relevant indicators are assessed.

    Second, Li Liming, the first director of the Chinese Center for Disease Control and Prevention and a professor at the School of Public Health of Peking University, told the reporter of Global magazine that the most important thing is to create a better drug research and development environment and encourage domestic drugs to truly reduce the burden on domestic medicine.
    Companies, including private pharmaceutical companies, actively carry out drug research and development, and social charity organizations should also vigorously support the research and development of pharmaceutical companies and provide financial support.

    Second, Li Liming, the first director of the Chinese Center for Disease Control and Prevention and a professor at the School of Public Health of Peking University, told the reporter of Global magazine that the most important thing is to create a better drug research and development environment and encourage domestic drugs to truly reduce the burden on domestic medicine.
    Companies, including private pharmaceutical companies, actively carry out drug research and development, and social charity organizations should also vigorously support the research and development of pharmaceutical companies and provide financial support.
    Second, Li Liming, the first director of the Chinese Center for Disease Control and Prevention and a professor at the School of Public Health of Peking University, told the reporter of Global magazine that the most important thing is to create a better drug research and development environment and encourage domestic drugs to truly reduce the burden on domestic medicine.
    Companies, including private pharmaceutical companies, actively carry out drug research and development, and social charity organizations should also vigorously support the research and development of pharmaceutical companies and provide financial support.

    "If there is no new drug with China's independent intellectual property rights, we will always pay foreign pharmaceutical companies' high intellectual property fees and high drug costs, and the goal of reducing medical costs will never be achieved.
    " Li Liming emphasized.

    “,,。”。“,,。”。

    ,,“”,。

    ,,“”,。,,“”,。

    “,1983《》,,。,‘’‘’。,,。,。。”,,,,;;;;。

    “,1983《》,,。,‘’‘’。,,。,。。”,,,,;;;;。“,1983《》,,。,‘’‘’。,,。,。。”,,,,;;;;。

    ,,,,,“”,。

    ,,,,,“”,。,,,,,“”,。

    “,()(/,/),。,‘’(、),,‘’。,,。”。(《》,:)

    “,()(/,/),。,‘’(、),,‘’。,,。”。(《》,:)“,()(/,/),。,‘’(、),,‘’。,,。”。(《》,:)

     

    html">· MDT
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.